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The cellular events involved in acetyl-l-carnitine (ALCAR) analgesia were investigated in the mouse hot plate test. I.c.v. pre-
treatment with aODNs against the a subunit of Gq and G11 proteins prevented the analgesia induced by ALCAR (100 mg kg
1
s.c. twice daily for 7 days). Administration of the phospholipase C (PLC) inhibitors U-73122 and neomycin, as well as the injec-
tion of an aODN complementary to the sequence of PLCb1, antagonized the increase of the pain threshold induced by ALCAR.
Pretreatment with U-73343, an analogue of U-73112 inactive on PLC, did not modify ALCAR analgesic effect. In mice under-
going treatment with LiCl, which impairs phosphatidylinositol synthesis, or pretreatment with TMB-8, a blocker of Ca++ release
from intracellular stores, the antinociception induced by ALCAR was dose-dependently antagonized. I.c.v. treatment with hep-
arin, an IP3 receptor antagonist, prevented the increase of pain threshold induced by the investigated compound, analgesia that
was restored by co-administration of d-myo-inositol. On the other hand, i.c.v. pretreatment with the selective protein kinase C
(PKC) inhibitors calphostin C and cheleritryne, resulted in a dose-dependent potentiation of ALCAR antinociception. The
administration of PKC activators, such as PMA and PDBu, dose-dependently prevented the ALCAR-induced increase of pain
threshold. Neither aODNs nor pharmacological treatments produced any behavioral impairment of mice as revealed by the rota-
rod and hole board tests. These results indicate that central ALCAR analgesia in mice requires the activation of the PLC-IP3
pathway. By contrast, the simultaneous activation of PKC may represent a pathway of negative modulation of ALCAR anti-
nociception.
# 2004 Elsevier Ltd. All rights reserved.
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Acetyl-l-carnitine (c-trimethyl-b-acetylbutyrobetaine;
ALCAR), the acetyl ester of carnitine, is a small water-
soluble molecule naturally present in the central ner-
vous system involved in a wide variety of physiological
functions. In the last decade, a role of ALCAR in the
modulation of pain perception has been postulated.
ALCAR has been demonstrated to be significantly
effective in reducing neuropathic pain, a conditioncharacterized by spontaneous pain, allodynia and
hyperalgesia caused by traumatic injury, diabetes, and
viral infections. Intramuscular chronic treatment with
ALCAR significantly improves the outcome of painful
neuropathies or radiculopathies (Onofrj et al., 1995). A
beneficial effect of ALCAR has been reported in the
treatment of symptomatic diabetic neuropathy
(Quatraro et al., 1995) and in the treatment of pain in
distal symmetrical polyneuropathy related to HIV
infection (Scarpini et al., 1997). More recently it has
been reported that ALCAR induces antinociception by
a central indirect cholinergic mechanism (Ghelardini
et al., 2002). An up-regulation of mGlu2 receptors in
ALCAR-treated animals has also been postulated
(Chiechio et al., 2002). Literature data reported that
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vation of the muscarinic system are blocked not only
by scopolamine, but also by the Glu2 receptor antag-
onist LY341495 (Johnson et al., 2000), indicating the
presence of a correlation between the glutamatergic
and muscarinic system, being the muscarinic system
activation downstream to the mGlu2 receptors up-
regulation.
Numerous reports have provided evidence for the
critical involvement of the cholinergic system in pain
inhibitory pathways. Several literature reports indicate
that cholinergic antinociception induced both directly,
through muscarinic agonists, and indirectly, by enhanc-
ing ACh extracellular levels through cholinesterase
inhibitors, is mediated by M1 receptor stimulation, evi-
dencing that M1 muscarinic receptor subtype plays an
essential role in the modulation of pain perception.
(Bartolini et al., 1992; Iwamoto and Marion, 1993;
Ghelardini et al., 1996; Naguib and Yaksh, 1997; Ghe-
lardini et al., 2000).
The five types of mammalian muscarinic receptors,
m1 through m5, differ in primary structure as determ-
ined by molecular cloning (Caulfield, 1993). It is well
established that ‘‘odd-numbered’’ muscarinic receptors
(M1–M3–M5) typically couple via the a subunits of the
Gq/11 family to activate phospholipase C (PLC), stimu-
lating phosphoinositide (PI) hydrolysis (Caulfield and
Birdsall, 1998). In particular, reconstitution experi-
ments with purified m1 receptors, G protein subunits
and PLC suggested that the b1 subtype of PLC serves
as the primary effector for the m1 receptor (Felder,
1995). Receptor-mediated activation of PLC results in
the generation of at least two messengers, inositol-
1,4,5-triphosphate (IP3) and diacylglycerol (DAG). The
main effect of DAG is to activate protein kinase C
(PKC); the effect of IP3 is to release Ca
++ stored in the
endoplasmic reticulum. The ‘‘even-numbered’’ mem-
bers (M2–M4) are preferentially coupled via Gi proteins
to inhibit adenylate cyclase (Caulfield and Birdsall,
1998). Expression studies revealed that the cloned m2
and m4 receptors also stimulate PLC, although with
lower efficiency than the PLC stimulation observed by
m1 or m3 receptors (Ashkenazi et al., 1987).
Recently, it has been reported that the activation of
the PLC-IP3 pathway is essential to induce cholinergic
antinociception in mice (Galeotti et al., 2003). Since it
has been demonstrated that ALCAR is able to increase
the pain threshold through a muscarinic mechanism,
the aim of the present study was to investigate the
intracellular mechanisms involved in ALCAR-mediated
antinociception in mice. In particular, we examined
whether the activation of PLC, and, subsequently, of
the DAG- and IP3-mediated intracellular pathways,
participates in the mechanism of central antinocicep-
tion following ALCAR administration.2. Methods
2.1. Animals
Male Swiss albino mice (24–26 g) from Morini (San
Polo d’Enza, Italy) were used. Twelve mice were
housed per cage. The cages were placed in the experi-
mental room 24 h before the test for acclimatization.
The animals were fed a standard laboratory diet and
tap water ad libitum and kept at 22 1 vC with a 12 h
light/dark cycle, light at 7 a.m. All experiments were
carried out in accordance with the NIH Guide for the
Care and Use of Laboratory animals. All efforts were
made to minimize animal suffering, and to reduce the
number of animals used.2.2. Hot-plate test
The method adopted was described by O’Callaghan
and Holtzman (1975). Mice were placed inside a stain-
less steel container, which was set thermostatically at
52:5 0:1 vC in a precision water-bath from KW
Mechanical Workshop, Siena, Italy. Reaction times (s),
were measured with a stopwatch before and 15, 30, 45
and 60 min after the beginning of the test. The end-
point used was the licking of the fore or hind paws.
Those mice scoring less than 12 and more than 18 s in
the pretest were rejected (30%). An arbitrary cut-off
time of 45 s was adopted. The selection of mice by
pretest values was performed before the beginning of
ALCAR treatment. The pretest was also performed the
day of the test in order to evaluate a possible analgesic
effect induced by the treatment, but in this moment no
animal was discarded.
The licking latency values reported in each figure are
measured 30 min after the beginning of the test. Drugs
were injected in order to obtain their maximum effect
in correspondence to the 30 min after the beginning of
the test.2.3. Rota-rod test
The apparatus consisted of a base platform and a
rotating rod with a diameter of 3 cm and a non-slip-
pery surface. The rod was placed at a height of 15 cm
from the base. The rod, 30 cm in length, was divided
into five equal sections by six disks. Thus, up to five
mice were tested simultaneously on the apparatus, with
a rod-rotating speed of 16 rpm. The integrity of motor
coordination was assessed on the basis of the number
of falls from the rod in 30 s according to Vaught et al.
(1985). Those mice scoring less than three and more
than six falls in the pretest were rejected (20%). The
performance time was measured before (pretest) and
15, 30 and 45 min after the beginning of the test. The
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chronically treated with ALCAR.2.4. I.c.v. injection technique
I.c.v. administration was performed under ether
anesthesia with isotonic saline as solvent, according to
the method described by Haley and McCormick
(1957). During anesthesia, mice were grasped firmly by
the loose skin behind the head. A hypodermic needle
(0.4 mm external diameter) attached to a 10 ll syringe
was inserted perpendicularly through the skull and no
more than 2 mm into the brain of the mouse, where
5 ll solution were then administered. We have put a
restrictor on the hypodermic needle to ensure that the
needle was inserted no more than 2 mm. The injection
site was 1 mm to the right or left from the midpoint on
a line drawn through to the anterior base of the ears.
Injections were performed randomly into the right or
left ventricle. To ascertain that solutions were adminis-
tered exactly into the cerebral ventricle, some mice
were injected with 5 ll of diluted 1:10 India ink and
their brains were examined macroscopically after sec-
tioning. The accuracy of the injection technique was
evaluated with 95% of injections being correct.2.5. Drugs
The following drugs were used: acetyl-l-carnitine
(Sigma-Tau, Italy); TMB-8 (8-(N,N-diethylamino)-
octyl-3,4,5-trimethoxybenzoate) hydrochloride, heparin
sodium salt (Mol. Wt: approx. 60,000), lithium chlor-
ide, (Sigma, Milan, Italy); calphostin C, chelerytrine,
U-73122 (1-[6-((17b-3-methoxyestra-4,3,5(10)-trien-
17-yl)amino)hexyl]1H-pyrrole-2,5-dione), U-73343
(1-[6-[[17b-3-methoxyestra-1,3,5(10)-trien-17-yl]amino]-
hexyl]-1H-pyrrolidinedione), neomycin sulphate, d-myo
inositol 1,4,5-trisphosphate hexasodium salt, phorbol-
12,13-dibutyrate (PDBu), phorbol-12-myristate-13-
acetate (PMA) (Calbiochem, Milan, Italy). Other
chemicals were of the highest quality commercially
available. U-73122, U-73343, calphostin C, cheleri-
tryne, PMA, PDBu were dissolved in 0.5% DMSO
whereas all other drugs were dissolved in isotonic
(NaCl 0.9%) saline solution immediately before use.
Drug concentrations were prepared so that the neces-
sary dose could be administered in a volume of 5 ll per
mouse by intracerebroventricular (i.c.v.) injection and
10 ml kg1 by subcutaneous (s.c.) injection. ALCAR
was administered twice daily for 7 days. The last injec-
tion of ALCAR was performed the day before the
beginning of experiments and, exactly, 12 h prior to the
test. Therefore, the licking latency values reported in
each figure for the ALCAR-treated group represent the
effect produced by a 7-day treatment with ALCAR.
PMA, PDBu and Calphostin C where injected i.c.v. 1 hbefore the test; chelerytrine was injected 90 min before
the test; LiCl was administered s.c. 18 h before the test;
U-73122, U-73343, neomycin, TMB-8, heparin, d-myo
inositol were injected 15 min before behavioral tests.
Doses and administration schedule were chosen on the
bases of time-course and dose–response experiments
previously performed in our laboratory. Furthermore,
literature data confirm the selectivity and efficacy of the
above-mentioned treatments at time and concentration
used.2.5.1. Antisense oligonucleotides
Phosphodiester oligonucleotides (ODNs) protected
by terminal phosphorothioate double substitution (cap-
ped ODNs) against possible exonuclease-mediated
degradation were purchased from Tib-Molbiol (Genoa,
Italy). The sequences are the following: anti-Gqa: 5
0-
CGG CTA CAC GGT CCA AGT CAT-30, corre-
sponding to nucleotides 484–504 of the Gqa sequence;
anti-G11a: 5
0-CTG TGG CGA TGC GGT CCA
CGT-30, corresponding to nucleotides 487–507 of the
G11a sequence; anti-PLCb1: 50-G
CT GTC GGA CAC
GCA-30, corresponding to nucleotides 49–63 of the
PLCb1 gene sequence. All aODNs were previously
characterized by in vitro and in vivo experiments (San-
chez-Blazquez and Garzon, 1998). We also confirmed
the aODN effect on Ga and PLCb1 protein levels by
performing immunoblotting experiments. We observed
a statistically significant reduction of the expression of
Gqa, G11a and PLCb1 after aODN treatment in com-
parison with mice treated with dODN (data not
shown). A 21-mer fully degenerated ODN (dODN) 50-
NNN NNN NNN NNN NNN NNN NNN-30
(where N is G, or C, or A, or T) and a 15-mer fully
degenerated ODN (dODN) 50-NNN NNN NNN
NNN NN N-30 (where N is G, or C, or A, or T) were
used as a control respectively for the 21-mer anti-Gqa
and anti-G11a and for the 15-mer anti-PLCb1. ODNs
were vehiculated intracellularly by an artificial cationic
lipid (DOTAP, Sigma, Italy) to enhance both uptake
and stability. aODN or dODN were preincubated at 37
v
C for 30 min with 13 lM DOTAP and supplied to
mice by i.c.v. injection of 5 ll solution 72, 48 and 24 h
prior to the behavioral tests.2.6. Statistical analysis
All experimental results are given as the mean
S:E:M. An analysis of variance ANOVA, followed by
Fisher’s Protected Least Significant Difference pro-
cedure for post-hoc comparison, were used to verify
significance between two means of behavioral results.
Data were analyzed with the StatView software for the
Macintosh (1992). P values of less than 0.05 were con-
sidered significant.
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3.1. Role of Gqa and G11a on ALCAR antinociception
Previous experiments performed in our laboratory
showed an analgesic effect induced by ALCAR
(100 mg/kg sc administered twice daily for 7 days) that
persisted up to 7 days after the end of the 7-day treat-
ment. The increase of the pain threshold induced by
ALCAR disappeared 21 days after the end of the treat-
ment (Ghelardini et al., 2002).
The effect of pretreatment with antisense ODNs
(aODN) to the a subunit of Gq and G11 proteins on
ALCAR (100 mg kg1 s.c. twice daily for 7 days)
induced antinociception was evaluated in the mouse
hot-plate test. Anti-Gqa (3 nmol per mouse i.c.v.) and
anti-G11a (3 nmol per mouse i.c.v.) antagonized the
increase of the pain threshold produced by ALCAR
(Fig. 1). The aODNs, when injected alone, did not
modify the pain threshold in comparison with control
animals. Furthermore, the i.c.v. injection of dODN
(3 nmol per mouse i.c.v.), used as control, neither
modified the licking latency of mice nor altered the sen-
sitivity to analgesic drugs in comparison with saline-
pretreated animals (Fig. 1).3.2. Role of PLCb1 on ALCAR antinociception
The administration of the PLC inhibitor U-73122
prevented ALCAR (100 mg kg1 s.c. twice daily for 7
days) antinociception. The dose of 0.6 lg per mouse
i.c.v. was devoid of any effect whereas a complete pre-
vention was reached at 2.5 lg per mouse i.c.v. (Fig. 2).By contrast, U-73343 (2.5 lg per mouse i.c.v.), an ana-
logue of U-73122 inactive on PLC, used as negative
control, did not alter the increase of pain threshold
produced by ALCAR (Fig. 2).
The PLC inhibitor neomycin (10 lg per mouse i.c.v.)
prevented the ALCAR analgesic effect. At a lower dose
(5 lg per mouse i.c.v.) neomycin was devoid of any
effect (Fig. 2).
Pretreatment with an anti-PLCb1 (3 nmol per mouse
i.c.v.) prevented the increase of the pain threshold
induced by ALCAR (Fig. 2). The i.c.v. injection of
dODN (3 nmol per mouse i.c.v.), used as control,
neither modified the licking latency of mice nor altered
the sensitivity to analgesic drugs in comparison with
naive and saline-treated animals (data not shown).
U-73122, neomycin and anti-PLCb1, when injected
alone, produced neither a hyperalgesic nor an analgesic
effect (Fig. 2).
3.3. Role of IP3 on ALCAR-induced antinociception
Pretreatment with LiCl, which impairs phosphatidy-
linositol synthesis, 18 h before the test dose-depen-
dently reduced the antinociception induced by ALCAR
(100 mg kg1 s.c. twice daily for 7 days). LiCl, at
40 mg kg1 s.c., was devoid of any effect. The dose of
LiCl of 200 mg kg1 s.c. reduced ALCAR analgesic
effect without reaching the statistical significance
whereas the dose of 400 mg kg1 s.c. significantly
prevented the increase of the pain threshold induced
by the cholinesterase inhibitor. The injection of LiCl
(40–400 mg kg1 s.c.) alone did not modify the lickingFig. 1. Prevention by pretreatment with anti-Gqa (3 nmol per mouse
i.c.v.) and anti-G11a (3 nmol per mouse i.c.v.) of ALCAR (100 mg
kg1 s.c. twice daily for 7 days)-induced antinociception in the mouse
hot-plate test. The licking latency values were recorded 30 min after
the beginning of the test. ODNs were administered 72, 48 and 24 h
prior to the behavioral tests. Vertical lines represent s.e. mean.
P < 0:05 in comparison with saline, ^P < 0:05 in comparison with
dODNþALCAR-treated mice. The number of animals ranged
between 15 and 18.Fig. 2. Prevention by pretreatment with U-73122 (0.6–2.5 lg per
mouse i.c.v.), neomycin (5–10 lg per mouse i.c.v) and anti-PLCb1
(3 nmol per mouse i.c.v.) of ALCAR (100 mg kg1 s.c. twice daily
for 7 days)-induced antinociception in the mouse hot-plate test. The
licking latency values were recorded 30 min after the beginning of the
test. The vehicle is: 0.5% DMSO for U-73122 and U-73343, saline for
neomycin, dODN for anti-PLCb1. ODNs were administered 72, 48
and 24 h prior to the behavioral tests. P < 0:05 in comparison with
control group, ^P < 0:05 in comparison with ALCAR-treated mice.
The number of animals ranged between 14 and 16.
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animals (Fig. 3).
The administration of heparin (1–40 lg per mouse
i.c.v.), an antagonist of IP3 receptors, prevented the
increase of the pain threshold induced by ALCAR
(100 mg kg1 s.c. twice daily for 7 days) (Fig. 4). The
dose of heparin of 1 lg per mouse i.c.v. was devoid of
any effect. Co-administration of d-myo-inositol (1 lg
per mouse i.c.v.) reverted the heparin-induced antagon-istic effect, whereas, at the dose of 0.1 lg per mouse
i.c.v did not modify the antagonistic effect produced by
heparin (Fig. 4).
TMB-8, a blocker of Ca++ release from intracellular
stores, antagonized ALCAR (100 mg kg1 s.c. twice
daily for 7 days) antinociception. The dose of TMB-8
of 0.01 lg per mouse i.c.v. was ineffective; the dose of
0.1 lg per mouse i.c.v. reduced the increase of the pain
threshold induced by the ALCAR without reaching the
statistical significance whereas the maximum antagon-
istic effect was reached at 1 lg per mouse i.c.v. (Fig. 4).
TMB-8, when administered alone, did not modify the
licking latency values in comparison with control ani-
mals (Fig. 4).3.4. Role of PKC on ALCAR-induced antinociception
Pretreatment with the PKC blocker calphostin C
produced a dose-dependent potentiation of ALCAR
(100 mg kg1 s.c. twice daily for 7 days) antinocicep-
tion in the mouse hot-plate test. The maximum effect
was obtained at the dose of 0.1 lg per mouse i.c.v. The
dose of 0.01 lg per mouse i.c.v. was devoid of any
effect (Fig. 5). Similarly to calphostin C, cheleritryne,
another PKC blocker, potentiated the antinociceptive
effect of ALCAR at the dose of 2.5 lg per mouse
(Fig. 5).
Calphostin C and cheleritryne potentiated the
increase of the pain threshold induced by ALCAR,
without modifying the mouse pain threshold when
administered alone (Fig. 5).
The PKC activators PDBu (10–40 pmol per mouse
i.c.v.) and PMA (1–15 pmol per mouse i.c.v.) dose-
dependently antagonized the analgesia induced byFig. 3. Prevention by pretreatment with LiCl (40–400 mg kg1 s.c.)
of ALCAR (100 mg kg1 s.c. twice daily for 7 days)-induced anti-
nociception in the mouse hot-plate test. The licking latency values
were recorded 30 min after the beginning of the test. Vertical lines
represent s.e. mean.
v
P < 0:05 in comparison with saline-treated
mice, P < 0:05 in comparison with ALCAR-treated mice. The num-
ber of animals ranged between 13 and 15.Fig. 4. Prevention by TMB-8 (0.01–1 lg per mouse i.c.v.) and
heparin (1–40 lg per mouse i.c.v.) of ALCAR (100 mg kg1 s.c. twice
daily for 7 days)-induced antinociception in the mouse hot-plate test
and reversal of heparin antagonism by d-myo-inositol (1 lg per
mouse i.c.v.). Vertical lines represent s.e. mean. P < 0:05 in compari-
son with saline-treated mice;
v
P < 0:05 in comparison with ALCAR-
treated mice. The number of animals ranged between 14 and 18.Fig. 5. Potentiation by calphostin C and cheleritryne of ALCAR
(100 mg kg1 s.c. twice daily for 7 days)-induced antinociception in
the mouse hot-plate test. The licking latency values were recorded
30 min after the beginning of the test. Vertical lines represent s.e.
mean. P < 0:05 in comparison with ALCAR-treated mice. The num-
ber of animals ranged between 12 and 16.
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(Fig. 6). The maximum antagonistic effect of PDBu
and PMA was obtained, respectively, at the dose of 40
and 15 pmol per mouse i.c.v.; at the highest effective
doses the two PKC activators did not modify the ani-
mals’ licking latency values in comparison with control
animals (Fig. 6).3.5. Effect of treatments on mouse behavior
The compounds investigated, at the highest effective
doses, were tested in order to assess their effect on
mouse behavior. Mice pretreated with aODNs (3.0
nmol per mouse i.c.v.), dODN (3.0 nmol per mouse
i.c.v.), LiCl (400 mg kg1 s.c.), TMB-8 (1 lg per mouse
i.c.v.), d-myo inositol (1 lg per mouse i.c.v.), heparin
(40 lg per mouse i.c.v.), U-73122 (2.5 lg per mouse
i.c.v.), U-73343 (2.5 lg per mouse i.c.v.), neomycin
(10 lg per mouse i.c.v.), calphostin C (0.1 lg per
mouse i.c.v.), cheleritryne (2.5 lg per mouse i.c.v.),
PMA (15 pmol per mouse i.c.v.), PDBu (40 pmol per
mouse i.c.v.) were evaluated for motor coordination by
use of the rota-rod test, and for spontaneous motility
and inspection activity by use of the hole board test.
The endurance time, evaluated before and 15, 30 and
45 min after the beginning of the rota-rod test, showed
the lack of any impairment in the motor coordination
of animals pretreated with aODNs in comparison with
dODN group. Mice pretreated with LiCl, TMB-8, d-
myo inositol, heparin, neomycin or pretreated with U-
73122, U-73343, calphostin C, cheleritryne, PMA,
PDBu did not show any alteration of motor coordi-
nation in comparison, respectively, with saline orvehicle group (Fig. 7). In order to further exclude any
impairment of motor coordination induced by the
above-mentioned treatments, we also performed the
rota rota test by pretraining animals and obtaining the
same results (data not shown).
Higher doses of the intracellular modulators
employed were not investigated since they induced
behavioral side effects such as tremors and convulsions.4. Discussion
ALCAR antinociception has been reported to under-
lie the indirect activation of the central muscarinic sys-
tem (Ghelardini et al., 2002). The present study
investigated the intracellular mechanism involved in
ALCAR-induced increase of pain threshold in a con-
dition of acute thermal nociception in mice and
demonstrated the importance of the activation of the
PLC-IP3 pathway in ALCAR analgesia.
Several PLC inhibitors are currently available. U-
73122, an aminosteroid, has been found to be a potent
inhibitor of aggregation of human platelets induced by
a variety of agonists, and this compound has been fur-
ther characterized as an inhibitor of G protein-medi-Fig. 6. Prevention by pretreatment with PDBu (10–40 pmol per
mouse i.c.v.) and by PMA (1–15 pmol per mouse i.c.v.) of ALCAR
(100 mg kg1 s.c. twice daily for 7 days)-induced antinociception in
the mouse hot-plate test. The licking latency values were recorded 30
min after the beginning of the test. Vertical lines represent s.e. mean.
P < 0:05 in comparison with saline-treated mice, ^P < 0:05 in com-
parison with ALCAR-treated mice. The number of animals ranged
between 13 and 16.Fig. 7. Lack of effect of intracellular pharmacological modulators
on motor coordination in the mouse rota-rod test in comparison with
saline (panel A) or vehicle (panel B). Vertical lines represent s.e.
mean. Ten animals per group were used.
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1992). Neomycin has been reported to inhibit hor-
mone-stimulated IP3 production through the blockade
of PLC (Phillippe, 1994). The administration of U-
73122 dose-dependently prevented the antinociception
induced by ALCAR. By contrast, U-73343, a succini-
mido analogue used as negative control for U-73122
being a weak inhibitor of PLC (Bleasdale et al., 1990;
Smith et al., 1990), did not modify the analgesia
induced by ALCAR suggesting that the prevention of
ALCAR-induced analgesia by U-73122 is mediated by
PLC activation. This hypothesis is also supported by
the reversal of ALCAR antinociception produced by
neomycin. Phosphoinositide-specific PLC represents a
family of isozymes found in eukaryotes composed by b,
c and d subtypes that cleaves the polar head group
from inositol lipids (Rebecchi and Pentyala, 2000).
Present results indicate that ALCAR activates the PLC
pathway and provides evidence for the involvement of
the PI-specific PLC (PLCb). Among the PLCb sub-
family, the isozyme PLCb1 has been reported to be
selectively activated by M1 receptors (Felder, 1995), a
muscarinic receptor subtype mainly involved in the
induction of muscarinic analgesia (Ghelardini et al.,
2000). In order to elucidate the role of this PLC sub-
type in ALCAR antinociception, an aODN comp-
lementary to the sequence of PLCb1 was employed.
The inhibition of the expression of this isozyme pre-
vented the increase of pain threshold induced by
ALCAR. These results indicate PLC, and in particular
the isozyme PLCb1, as an important intracellular effec-
tor in the analgesic effect induced by the investigated
compound.
The ‘‘odd-numbered’’ muscarinic receptors activate
PLC via the a subunit of the Gq/11 proteins (Caulfield
and Birdsall, 1998). Furthermore, activation of PLCb1 is
achieved with the help of Ga subunits of the Gq proteins
(Taylor et al., 1991). The administration of aODNs
against the a subunit of Gq and G11 proteins antagonized
the ALCAR antinociception. These results indicate that
the stimulation of the PLC-mediated intracellular path-
way in ALCAR analgesia requires the receptor-mediated
activation of Gq/11 transducer proteins.
PLC isozymes hydrolyze the highly phosphorylated
lipid phosphatidylinositol 4,5-biphosphate generating
two intracellular products: IP3, a universal calcium-
mobilizing second messenger, and DAG, an activator
of PKC. To investigate the IP3-mediated pathway,
LiCl, an uncompetitive inhibitor of inositol monopho-
sphatase, which regenerates inositol from inositol
monophosphate, was used. The LiCl-induced inhibition
depletes inositol and prevents the formation of IP3
(Kennedy et al., 1990; Phiel and Klein, 2001). Animals
pretreated with LiCl showed an impaired anti-
nociceptive response to administration of ALCAR sug-
gesting the involvement of the PLC-IP3 pathway in theintracellular mechanism of ALCAR. The role of IP3 in
ALCAR analgesia was also confirmed by the dose-
dependent prevention of the increase of pain threshold
induced by the above-mentioned compound by low
molecular weight heparin administration. A reversal of
the heparin antagonistic effect was obtained after co-
administration of d-myo inositol 1,4,5-trisphosphate,
further supporting the hypothesis of the activation of
the PLC-IP3 pathway in ALCAR analgesia. Heparin is
a potent and selective IP3 receptor antagonist (Jonas
et al., 1997). This compound must be injected into cells
or perfused onto permeabilized cells because of its high
molecular weight (12,000–13,000 Da) and lack of mem-
brane permeability. Some evidence indicates that the
low molecular weight heparin (6000 Da) used in this
study is membrane permeable. Perfusion of low mol-
ecular weight heparin over a non-permeabilized cer-
ebellar slice preparation attenuated glutamate-
stimulated increases in free intracellular Ca++ (Jonas
et al., 1997). IP3, through the interaction with specific
receptors located on the endoplasmic reticulum, causes
release of Ca++ from intracellular stores into the cyto-
plasm (Mignery and Sudhof, 1990; Ferris et al., 1992).
Since present results indicate the importance of IP3
production in the induction of ALCAR analgesia, we
thought it worthwhile to investigate the role played by
the variation of the intracellular Ca++ levels in the
mechanism of action of the investigated compound. To
this purpose, TMB-8, an agent that antagonizes the
mobilization of Ca++ from intracellular stores (Mala-
godi and Chiou, 1974), was used. Pretreatment with
TMB-8 dose-dependently antagonized the increase of
pain threshold induced by ALCAR, suggesting that the
release of Ca++ from intracellular stores induced by
IP3 is necessary to produce ALCAR analgesia.
In addition to inducing IP3 formation, PLC causes
the activation of PKC through stimulation of the pro-
duction of DAG (Rebecchi and Pentyala, 2000). The
involvement of PKC in the mechanisms that underlie
the development of acute and persistent pain has been
widely reported (Basbaum, 1999; Malmberg, 2000;
Zimmermann, 2001; Kamei et al., 2001). In the present
study, pretreatment with calphostin C and chelerytrine,
selective, potent and membrane-permeable PKC inhibi-
tors (Kobayashi et al., 1989; Herbert et al., 1990),
dose-dependently enhanced the analgesia induced by
ALCAR administration. Furthermore, activation of
PKC by phorbol esters, such as PMA and PDBu
(Nishizuka, 1992), antagonized the increase of pain
threshold induced by ALCAR. These data indicate that
activation of PKC constitutes a pathway involved in
negative modulation of the central antinociceptive
response induced by ALCAR.
The highest active doses of U-73122, U-73343, neo-
mycin, LiCl, heparin, TMB-8, PMA and PDBu, as well
as the inhibition of the expression of PLCb1, Gq and
N. Galeotti et al. / Neuropharmacology 47 (2004) 286–294 293G11 by means of selective aODNs, in the absence of co-
administration of ALCAR, did not reduced the licking
latency values of mice in comparison with control
groups. Similarly, calphostin C and cheleritryne, that
potentiated ALCAR analgesia, when injected alone,
did not increase mouse pain threshold. These results
exclude not only that the prevention of ALCAR anti-
nociception is due to hyperalgesic effect of the intra-
cellular modulators used, but also that the action
produced PKC blockers on ALCAR analgesia origins
from antinociceptive properties of the pharmacological
modulators employed.
The modulation of the intracellular events promoted
by PLC activation can induce several side effects. It is
widely known that the PKC activators PMA and
PDBu are convulsant (Smith and Meldrum, 1992) and,
similarly, LiCl can induce neurological toxicity char-
acterized by tremors, convulsion, ataxia (Kores and
Lader, 1997). All the compounds, at the highest active
doses employed in the present study, did not cause any
detectable modification in animals’ gross behavior. At
the same doses, all treatments did not impair motor
coordination nor modify spontaneous motility nor
inspection activity in comparison with control groups,
excluding that the results obtained were due to ani-
mals’ altered viability. It should be noted that higher
doses of intracellular modulators could not be investi-
gated since evident signs of toxicity, such as tremors,
convulsions, etc. appeared. The induction of toxicity
can also be considered as an indication not only of the
diffusion of these compounds in the brain, but also of
the consequent reaching of key targets by using the
administration schedule employed in the present study.
Present data evidence the role of PLC-IP3 pathway in
the induction of ALCAR analgesia in a condition of
acute thermal nociception in mice. Furthermore, the con-
comitant activation of PKC through DAG generation
induced by PLC activation might represent a mechanism
of negative modulation of ALCAR antinociception.Acknowledgements
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